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Abstract
Introduction: Although oestrogen is essential for the development of the normal breast, adult mammary stem
cells are known to be oestrogen receptor alpha (ER) negative and rely on paracrine signals in the mammary
epithelium for mediation of developmental cues. However, little is known about how systemic oestrogen regulates
breast cancer stem cell (CSC) activity.
Methods: Here, we tested the effects of oestrogen on CSC activity in vitro and in vivo and investigated which
paracrine signalling pathways locally mediate oestrogen effects.
Results: CSC-enriched populations (ESA+CD44+CD24low) sorted from ER positive patient derived and established
cell lines have low or absent ER expression. However, oestrogen stimulated CSC activity demonstrated by increased
mammosphere and holoclone formation in vitro and tumour formation in vivo. This effect was abrogated by the
anti-oestrogen tamoxifen or ER siRNA. These data suggest that the oestrogen response is mediated through
paracrine signalling from non-CSCs to CSCs. We have, therefore, investigated both epidermal growth factor (EGF)
and Notch receptor signals downstream of oestrogen. We demonstrate that gefitinib (epidermal growth factor
receptor (EGFR) inhibitor) and gamma secretase inhibitors (Notch inhibitor) block oestrogen-induced CSC activity in
vitro and in vivo but GSIs more efficiently reduce CSC frequency.
Conclusions: These data establish that EGF and Notch receptor signalling pathways operate downstream of
oestrogen in the regulation of ER negative CSCs.
Introduction
Normal mammary stem cells (MSC) are responsible for
the generation of adult mammary tissue and the distinct
cell types within it as well as the extensive remodelling
and enlargement of the gland during multiple cycles of
pregnancy [1,2]. Mammary development is controlled by
a variety of hormones, including oestrogen without
which development cannot occur [3]. Isolation of MSC
using cell sorting techniques has allowed extensive stu-
dies of this cell sub-population and it has been shown
that these cells lack oestrogen receptor alpha (ER) [4,5].
In order to respond to systemic hormone signalling,
these cells must, therefore, rely on local mediation of
the signals by ER positive cells. There is good evidence
that the epidermal growth factor receptor (EGFR) path-
way, via binding of the amphiregulin ligand, is responsi-
ble for paracrine signalling that induces epithelial
proliferation during ductal elongation of the mammary
tree, but it is unknown whether this signal affects stem
cells [6].
The development and progression of breast tumours
has been proposed to be driven by breast cancer stem
cells (CSC) identified by the cell surface phenotype ESA
+CD44+CD24low or aldehyde dehydrogenase (ALDH1)
activity [7,8]. CSCs generate tumour heterogeneity and
are able to reinitiate tumours in transplantation experi-
ments [7]. CSCs are thought to be responsible for
tumour recurrence as they have been shown to be
inherently resistant to therapies, such as chemotherapy
[9], radiotherapy [10] and endocrine treatment [11,12].
There have been conflicting reports about the effects
of oestrogen on breast CSCs with evidence reported
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that oestrogen can increase or decrease CSC number in
breast cancer cell lines [13,14]. We predicted that these
very different effects were due to the duration of hor-
mone deprivation [12] compared to growth in standard
conditions. In the current study, where oestrogen treat-
ment is initiated after hormone withdrawal, oestrogen
increases CSC activity and frequency measured both in
vitro and in vivo. This is likely to be through paracrine
regulation since breast CSCs are mainly ER negative.
Here we establish that the EGF and Notch receptor sig-
nalling pathways are strong candidates as paracrine
mediators of oestrogen effects on CSC activity.
Materials and methods
Patient samples
Pleural effusion samples (n = 3, see Additional file 1, Table
S1) were collected from patients with metastatic breast
cancer during standard therapeutic drainage procedures,
with fully informed consent (ethical approval was granted
by the Central Office for Research Ethics Committee,
study #05/Q1403/159). Following collection of metastatic
fluid, cells were pelleted by centrifugation at 800 g. Pellets
were resuspended in PBS and blood cells were removed by
centrifugation of the cell suspension through 0.5 volumes
of Lymphoprep solution (Axis Shield, Dundee, UK) at 600
g. Cells were cultured in DMEM:F12/20% FCS/0.1% non-
essential amino acid solution/2.5 mM L-glutamine/Pen-
Strep (Invitrogen, Paisley, UK).
Cell lines
Cell lines were purchased from the LGC Standards
(Middlesex, UK); MCF7 (HTB-22), T47D (HTB-133),
BT474 (HTB-20), MDA-MB-231 (HTB-26), authenti-
cated by multiplex PCR assay using the AmpF/STR sys-
tem (Life Technologies, Paisley, UK) and verified as
mycoplasma free.
Monolayers of MCF7, T47D and BT474 were grown
adherently in DMEM complete medium (DMEM/10%
foetal calf serum/2 mM L-glutamine/PenStrep) and
MDA-MB-231 were cultured as monolayer in RPMI
complete medium (RPMI/10% FCS/1% Sodium pyruvate/
2 mM L-glutamine/PenStrep). Cells were maintained in a
humidified incubator at 37°C at an atmospheric pressure
of 5% (v/v) carbon dioxide/air. Cells were passaged at
80% confluence with a sub-cultivation ratio of 1:4. Cell
lines were not cultured beyond 20 generations.
Clonogenic culture
Cells were plated at 50 cells/cm2 in adherent conditions
for 10 days (MCF7, T47D) or 6 days (MDA-MB-231).
Colonies were fixed and stained with 1% crystal violet/
70% ethanol and were classified by light microscopy.
Colonies that had undergone five or more divisions, that
is, containing 32 or more cells, were counted [15].
Mammosphere culture
A single cell suspension was prepared using enzymatic
(0.125% Trypsin-EDTA (Worthington Biochemical
Corporation, Lakewood, NJ, USA)), and manual disag-
gregation (25 gauge needle). A total of 500 cells/cm2
were plated in non-adherent conditions in mammo-
sphere medium (DMEM-F12/B27/20 ng/ml EGF/Pen-
Strep) for five days. Mammospheres (MS) greater than
50 μm were counted.
Flow cytometry
Samples were resuspended at ≤ 1 × 106 in 100 μl sorting
buffer (1% BSA/PBS) and incubated with 10 μl of primary
pre-conjugated antibody for 10 minutes at 4°C. Following
incubation the cells were washed with 1 ml PBS and cen-
trifuged at 800 g for two minutes. Antibodies include
ESA-FITC (Dako, Cambridge, UK, BerEP4, F0860), CD44-
APC (BD Pharmingen, Oxford, UK, 559942) and CD24-
PE (Beckman Coulter, High Wycombe, UK, IMI1428U)
For analysis, cells were resuspended in 500 μl of sort-
ing buffer and passed through a 40 μm sieve. Fluores-
cence was measured using the Becton Dickinson FACS
Calibur and analysed using WinMDI 2.8 software (The
Scripps Institute, La Jolla, CA, USA).
For sorting, cells were resuspended in 500 μl of
Hank’s buffered saline solution (HBSS, Sigma, Cam-
bridge, UK) and passed through a 40 μm sieve. Cells
were sorted, with HBSS as a sheath fluid, at 16 PSI
using the Becton Dickinson FACS ARIA (Oxford, UK).
Quantitative RT-PCR
RNA was extracted using the RNAeasy kit (Qiagen,
Manchester, UK) according to manufacturer’s instruc-
tions and RNA was quantified using the Nanodrop spec-
trophotometer (Thermo Fisher Scientific, Basingstoke,
UK). cDNA was produced using the Taqman reverse
transcription kit (Life Technologies). qRT-PCR was per-
formed using Sybrgreen (Bioline, London, UK) and was
analysed on the 7900 PCR machine (Life Technologies)
using custom PCR array plates (SA Biosciences, West
Sussex, UK).
Western blotting
Protein was separated on an SDS-polyacrylamide gel and
transferred to Hybond-C Extra nitrocellulose membrane
(GE Healthcare, Buckinghamshire, UK). Primary antibo-
dies included: SP1-ER (RM-9101-SO, Thermo Fisher
Scientific, Basingstoke, UK), Cleaved N1-ICD (100-401-
407, Rockland, Gilbertsville, USA), Delta1 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA, sc-12530), Delta4
(Abcam, Cambridge, UK, ab7280), Jagged1 (Santa Cruz
Biotechnology, sc-6011), Jagged2 (Santa Cruz Biotechnol-
ogy, sc-08157), Actin (Santa Cruz Biotechnology, sc-1616),
ERK (Abcam, ab2430) and ERK phospho-Y992 (Abcam,
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ab81440). Densitometry was performed using ImageJ soft-
ware (NIH, Bethesda, USA) which is freely available [16].
Mean band intensity was measured and fold change from
actin control was calculated.
Oestrogen treatment
Cells were plated in a monolayer at 1 × 104/cm2 in com-
plete medium for 24 hours. At 24 hour intervals the med-
ium was changed to low serum medium with decreasing
concentrations of charcoal stripped serum, from 10% to
1%. Charcoal stripped serum was prepared by mixing foe-
tal calf serum with dextran coated charcoal and heating
for 30 minutes at 55°C. Serum was then centrifuged at
1,000 g for 15 minutes to remove charcoal. Finally the
serum was passed through a 0.22 μm sieve.
Cells were then cultured for 48 hours with 0 to 1 μM
17b-estradiol to identify the best concentration. A total of
1 nM was selected as the lowest concentration which gave
significant changes (see Additional file 2, Figure S1) and
was used with or without 1 μM 4OH-tamoxifen.
siRNA
A SMARTpool of siRNA to ER (Thermo Scientific Dhar-
macon, ON-TARGET plus Human ESR1 (Fermentas
GBMH, St Leon-Rot, Germany) was used to transfect cells
using Lipofectamine 2000 (Invitrogen, Paisley, UK)
according to the manufacturer’s instructions in serum free
medium. After six hours medium was changed to com-
plete medium and cells were cultured as described above.
Inhibition of paracrine signalling
Inhibitors of Notch (10 μM DAPT) and EGFR (1 μM gefi-
tinib) signalling were added to oestrogen activated cell cul-
tures (1 nM 17 b-estradiol) at Day 1 of treatment.
In vivo limiting dilution
Cells were treated as detailed above in CSS medium ±
17b-estradiol ± inhibitors for 48 hours. Cells were col-
lected and resuspended at the desired dilution (10, 100
and 1,000 cells) in 50% Matrigel (BD Biosciences, Oxford,
UK)/MS medium before sub-cutaneous injection into
NOD SCID IL2gammaR knock out (NSG) mice. Slow
release oestrogen pellets were implanted sub-cutaneously
into mice two days before cell injection (0.72 mg, Innova-
tive Research of America (Sarasota, USA). Mice were
assessed for tumour presence twice weekly.
Xenograft embedding and immunohistochemistry
Tumours were formalin fixed and paraffin embedded.
Antigen retrieval was performed at 98°C at pH 9. Slides
were blocked with hydrogen peroxide and casein before
incubation with the primary antibody (PanCytokeratin -
#70622, DAKO, Cambridge, UK). Slides were then incu-
bated with Envision secondary followed by DAB (DAKO).
Statistical methods
Throughout the paper data are represented as mean ±
SEM taken over a minimum of three independent experi-
ments, unless otherwise stated. Statistical significance was
measured using parametric testing, assuming equal var-
iance, in the majority of experiments with standard t-tests
for two-paired samples used to assess difference between
test and control samples.
Analysis of variance was performed to assess changes
in in vivo tumour growth rate. To calculate CSC fre-
quency, the L-Calc software (The Walter and Eliza Hall
Institute of Medical Research, Parkville, USA) was used
which is freely available [17].
Results
Oestrogen stimulation increases the breast cancer stem
cell-like population
The effect of 17b-estradiol on the CSC proportion was
assessed in three ER positive patient derived cell samples,
three ER positive cell lines (MCF7, T47D and BT474) and
an ER negative cell line (MDA-MB-231). Following oestro-
gen deprivation for six days and then 48 hours culture in 1
nM 17b-estradiol, the mammosphere forming cell (MFC)
number was significantly increased in all ER positive but
not ER negative primary cells and cell lines (Figure 1A).
Holoclone forming cell (HFC) number also significantly
increased in the ER positive but not ER negative cell lines
(Figure 1B). ER positive cells also contained a significantly
higher number of ESA+CD44+CD24low cells following the
48 hour exposure to 17b-estradiol compared to control
conditions (Figure 1C).
To verify that this effect was due to activation of oestro-
gen signalling we first knocked down ER gene expression
using siRNA (Figure 2A). In cells cultured in the presence
of ER siRNA and 17b-estradiol, no significant increase in
MFC is seen, establishing ER as the major player in the
oestrogenic response (Figure 2B).
Next, to block ER signalling in primary cells and other
cell lines, cells were cultured in the presence of oestrogen
and the anti-oestrogen tamoxifen. This treatment effi-
ciently blocked 17b-estradiol effects on ER positive patient
derived cells and cell lines (Figure 2C) although primary 2
remained raised compared to control cells. HFC was also
reduced in cell lines (Figure 2D) but no changes in MFC
or HFC number were seen in ER negative cells.
Breast cancer stem cells have low expression of ER
In order to demonstrate whether the effects of oestrogen
and tamoxifen were direct, ER positive patient derived
cells (primary 2) and MCF7 cells were FACS sorted to
assess the oestrogen receptor status of the CSC enriched
ESA+CD44+CD24low sub-population (Additional file 3,
Figure S2 and Additional file 4, Figure S3 show gating
procedure and example. For more details see [18]). Cells
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were then lysed and ER expression was assessed by Wes-
tern blot. In both cases, CSC-enriched cells (Population
1, ESA+44+24low) had very low or absent receptor
expression compared to more differentiated tumour cells
(Figure 3A, B). Populations 2 to 4 (differentiated tumour
cells) expressed between 1.7- and 8-fold more ER in the
Figure 1 Oestrogenic effects on cancer stem cells. Cells were cultured for 48 hours in a monolayer in the presence of 1 nM 17b-estradiol or vehicle
control and CSC assays were performed in ER positive cells (primary, MCF7, T47D and BT474) and ER negative cells (231). (A) Mammosphere formation,
(B) holoclone formation and (C) expression of ESA+ CD44+ CD24low were measured. Means plotted ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001.
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primary cells and between 1.5- and 3.5-fold more ER in
MCF7 cells (P < 0.05).
Collection of anoikis resistant (AR) cells is another method
previously reported to enrich for the CSC population
[18,19]. Primary cells taken from an ER positive patient
derived sample (primary 3) and ER positive cell lines were
plated in non-adherent culture for 16 hours before protein
and RNA were prepared from the total and AR popula-
tions. In all cases the AR population showed low/no
expression of ER assessed by Western blot (Figure 3C) and
qRT-PCR and several fold lower levels of expression of
known oestrogen responsive genes compared to total cell
populations (Figure 3D). These findings indicate that para-
crine signals from the ER positive cells are required to initi-
ate increases in breast CSC number.
EGFR signalling plays a role in the oestrogenic effect on
breast cancer stem cells
In the normal breast, evidence suggests that the para-
crine oestrogen signal occurs via amphiregulin (AREG)
Figure 2 Knock-down or inhibition of ER signalling blocks the effect of 17b-estradiol. (A) Representative Western blot showing ER knock-
down with siRNA. (B) Cells were exposed to oestrogen and the effect of ER siRNA was assessed with mammosphere culture. Cells were cultured
for 48 hours in the presence of 1 nM 17b-estradiol ± tamoxifen before CSC assays were performed. (C) Mammosphere formation and (D)
holoclone formation were assessed. Fold change is normalised to control, untreated cells represented as line. Means plotted ± SEM, *P < 0.05,
**P < 0.01, ***P < 0.001 compared to E2 treated. # P < 0.05 compared to control cells.
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Figure 3 Breast cancer stem cells have low expression of ER. Cells were sorted based on surface markers to enrich for CSC. Representative
Western blot showing ER expression in sorted primary metastatic cells (A) and MCF7 cells (B). Anoikis resistant (AR) cells from primary metastatic
and cell lines (MCF7 and T47D) were collected for protein and RNA. (C) Representative Western blot showing expression of ER in total versus AR
cells, (D) mRNA expression level of ER (ESR1) and responsive genes in AR cells compared to total population. (E) Representative Western blot of
ERK and phosphorylated (actived) ERK following culture for 48 hours in monolayer ± 1 nM 17b-estradiol ± 1 μM tamoxifen or gefitinib. (F)
Mammosphere formation was assessed following culture with 1 nM 17b-estradiol ± gefitinib. Fold change is normalised to control, untreated
cells represented as line. Means plotted ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001 compared to E2 treated. # P < 0.05 compared to control cells.
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activation of the EGFR [6] and downstream phosphory-
lation of ERK [20]. We, therefore, measured activation
of ERK signalling by ER and assessed the effect of the
specific EGFR inhibitor gefitinib. Activation of ER sig-
nalling with 17b-estradiol caused increased phosphoryla-
tion of ERK which could be abrogated by treatment
with tamoxifen or gefitinib, suggesting that ligand depen-
dent ER signalling transactivates EGFR to phosphorylate
ERK (Figure 3E). In mammosphere culture, gefitinib sig-
nificantly reduced the effect of oestrogen in ER positive
primary cells and lines (Figure 3F). However, with the
exception of primary 3, the MFC remained significantly
higher compared to control cultures which were not
exposed to oestrogen. These findings support the hypoth-
esis that EGFR mediated paracrine signalling plays a role
in the response to oestrogen but suggests other paracrine
signals are also important.
Notch signalling is involved in the oestrogenic effect on
breast cancer stem cells
Next, we investigated Notch signalling as another likely
paracrine pathway since it has been reported [21] and we
confirm here that Notch1 signalling activity increases fol-
lowing exposure to oestrogen (Figure 4A). Ligands of the
Notch pathway are expressed at significantly lower levels
in the CSC enriched sub-populations (Figure 4B) similar
to the EGF ligand amphiregulin (Figure 3D) suggesting
signalling may be initiated by ligands derived from the
non-CSC sub-population. We predicted that Notch1
receptor signalling has a role in the oestrogenic response
of breast CSCs and tested this using a gamma secretase
inhibitor (GSI) known to specifically target Notch1 signal-
ling [18]. GSI significantly reduced the oestrogenic effect
on MFC in primary cells and MCF7 cells (Figure 4C) but
the MFC number remained significantly increased com-
pared to control MS cultures. However, GSI used in com-
bination with gefitinib caused MFC number to fall below
that seen in control conditions (Figure 4D). GSI had no
effect on ERK phosphorylation, (Figure 4E) suggesting that
the Notch and EGFR signalling pathways have distinct
roles in the mediation of local signalling. We conclude
from these data that both EGF and Notch1 receptor sig-
nalling are paracrine mediators of the effects of systemic
oestrogen on breast CSC activity.
Oestrogen stimulation increases tumour initiating cell
number
The effect of 17b-estradiol on CSC activity and fre-
quency, and its inhibition using tamoxifen, gefitinib and
GSI, was assessed with limiting dilution of cells injected
into NSG mice. The human cell origin of xenografts
was verified using human specific pan-cytokeratin stain-
ing (see Additional file 5, Figure S4). A total of 1,000
injected cells pre-treated with 17b-estradiol initiated
tumours (> 100 mm3) more quickly, and these tumours
grew at a significantly faster rate than those formed
from control cells or those treated with inhibitors (P <
0.001, Figure 5A).
Using L-Calc (Stem Cell Technologies, Grenoble,
France), analysis of positive tumour growth (calculated as
growth ≥ 100 mm3) across the limiting dilution series
allowed estimation of the CSC number/tumour initiating
cell frequency (TIF) within each treatment (Figure 5B).
TIF increased from 1:475 in control cells to 1:22 in those
treated with 17b-estradiol (P = 0.0019). Compared to
17b-estradiol treated cells those treated with tamoxifen,
GSI or gefitinib + GSI showed significantly reduce TIF
and levels in these cells were not significantly different to
control. The effect of 17b-estradiol does not appear to be
completely blocked by gefitinib and the TIF remains
higher than in control cells although not significantly
(1:107, P = 0.118). This suggests that gefitinib alone is
not able to completely block the effect of oestrogen but
when used in combination with a Notch inhibitor it can
increase efficiency.
Discussion
Our data show that breast CSC activity and cell surface
marker expression is increased by oestrogen exposure.
This effect is observed in all ER positive patient-derived
primary cells and cell lines tested and can be demon-
strated both in vitro, using mammosphere and holoclone
culture, or in vivo, with limiting dilution analysis. We
demonstrate that the CSC-enriched populations have
low/no expression of ER suggesting that the effect seen is
not a direct one and we establish EGF and Notch recep-
tor signalling pathways as important paracrine mediators
of oestrogen effects on CSC activity.
The data presented here are supportive of previously
published work by Fillmore et al. [13] but contradicts
other reports showing decreased CSC activity in the pre-
sence of oestrogen [14]. We hypothesise that this is due to
differences in experimental design in these reports. Simões
et al. [14] exposed cells in non-adherent mammosphere
culture to oestrogen and, therefore, affected the CSC
population during anoikis resistance and MS formation. In
this paper, like Fillmore et al., we withdrew hormones and
then incubated monolayer cultures of breast cancer cells
with oestrogen before measurement of the CSC popula-
tion changes. This suggests that in adherent culture oes-
trogen affects the proliferation and/or self-renewal of CSC
whilst in non-adherent culture it may affect the survival or
activity of CSC in a different way.
Previously published data show that sub-populations
enriched for CSC have low expression of the oestrogen
receptor [13,22] but our data extend these findings to
show decreased ER signalling within the CSC enriched
population from metastatic ER positive patient samples.
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Figure 4 Systemic oestrogen signalling is mediated by EGFR and Notch. (A) Representative Western blot showing expression of cleaved
(active) Notch1 (N1-ICD) following culture ± 1 nM 17b-estradiol ± 10 μM GSI. (Bi) Representative Western blot showing expression of Notch
ligands in sorted MCF7 cells (left) and, where available, metastatic cells (right). (Bii) Densitometric analysis of three independent repeats of MCF7
sorting and of a single experiment for primary cells. Comparisons between population 1 (CSC enriched) and other populations are displayed. (C
and D) Mammosphere formation was assessed following culture with 1 nM 17b-estradiol ± gamma secretase inhibitor (GSI) alone and in
combination with gefitinib. Fold change is normalised to control, untreated cells represented as line. (E) Representative image of protein levels
of ERK and phosphorylated (actived) ERK following culture for 48 hours in monolayer ± 10 μM GSI. Means plotted ± SEM, *P < 0.05, **P < 0.01,
***P < 0.001 compared to E2 treated. # P < 0.05 compared to control cells.
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The paracrine mediation of oestrogen signalling occurs
in the normal breast through the EGFR pathway which
activates ERK signalling and we demonstrate that this is
also true in breast cancer. The inhibition of EGFR signal-
ling does not, however, completely block the oestrogenic
effects on CSC. An additive effect was seen when Notch
inhibition with GSI was combined with gefitinib. This is
supportive of recently published data which show an addi-
tive effect of EGFR/Notch inhibition on CSC activity in
primary human ductal carcinoma in situ [23].
Notch1 was seen to increase as a result of oestrogen sti-
mulation. In the normal breast, Notch1 is thought to play
a role in the early luminal progenitor cells rather than
stem cells and an analogous situation may, therefore, exist
Figure 5 In vivo assessment of oestrogenic effect on breast cancer stem cells. (A) Growth curves for xenografts produced from 1,000 cells
pre-treated ± 17b-estradiol, ± inhibitors. *P = 0.01 (B) In vivo tumour formation in each group represented as mice positive for growth/mice
tested displayed for each cell number tested. Tumour initiating cell frequency (95% CI) estimates calculated from limiting dilution analysis.
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in cancers, whereby oestrogen exerts its effects on early
differentiation progenitors of the CSC, rather than the
CSC itself. This may suggest that early progenitor cells are
directed to remain in a less differentiated state or that they
de-differentiated into a more CSC-like cell type.
The data presented here are not directly in agreement
with the previously published data showing FGF/Tbx3
signalling is responsible for this paracrine signalling in
cancers [13]. There is, however, crosstalk between the
two pathways and both are responsible for increased
Figure 6 Schematic representation of signals involved in paracrine mediation of systemic oestrogen signalling. The signal sending cell
(white) responds to oestrogen (E2) and initiates EGFR, FGFR and Notch ligand production. A signalling cascade is initiated within the signal
receiving cell (grey) which includes, but may not be limited to ERK, Tbx3 and Pea3 signalling. This drives increased CSC activity. This signal
mediation can be blocked by tamoxifen, gefitinib and gamma secretase inhibitors (GSI).
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ERK signalling [20,24]. It is possible, therefore, that both
pathways are involved in the oestrogenic response of the
ER negative CSC/progenitor population. Furthermore,
links between Tbx3 and Pea3 [25], a modulator of Notch
signalling [26], support the crosstalk among EGF, FGF and
Notch being responsible for CSC changes in response to
oestrogen. A putative model for the paracrine signalling
suggested by our results and the interactions identified by
others is depicted in Figure 6.
Conclusions
In summary, our findings provide more evidence for the
ER negative/low status of breast CSC in ER positive cell
lines and patient derived samples. CSC number and
activity increases in response to oestrogen stimulation
and, as in the normal breast, this effect is partly
mediated by EGFR signalling. We have further demon-
strated that Notch signalling also plays a role in the sti-
mulation of CSC expansion by oestrogen. The paracrine
signals that mediate the oestrogenic effects on CSC sug-
gest a role for EGFR and Notch signalling in endocrine
resistance and may offer suitable targets for treatment
of these tumours.
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